1111-P: Predictors of Type 2 Diabetes (T2D) Medication Change and Improved A1C among Older Adults Post-hospitalization

Introduction 8% at 180 days post-discharge in a subsample of patients with medication change and for whom the change preceded A1c testing. Predictors of medication change and A1c 8% post-hospitalization were modeled using logistic regressions. Results: The cohort included 359 patients, mean (SD) age 74 (±7) y, 61% White, 95% non-Hispanic, 51% female, 48% married, and 85% had Medicare. All patients were followed for six months. Treatment changes occurred in 65% of patients within 30 days and 82% within 90 days from discharge, with mean days to treatment change as 31 (95%CI: 26, 35). Patients with higher A1c values pre-hospitalization, A1c tests during hospitalization, and higher readmission risk were more likely to have medication changes. A1c data was available in N=289 (81%) patients at 6 months. The proportion achieving A1c 8% at 180 days was 42% (121/289) but significantly higher among those who had treatment change within 30 days (51% vs. 14%, p=0.003; OR=3.22, 95%CI: 1.01,10.21). Lower A1c value pre-hospitalization and A1c testing during hospitalization were also associated with A1c 8%. Conclusion: A1c testing during hospitalization was an important predictor for treatment change and improved A1c levels in older patients with T2D with A1c u/u8%. Recognition of the hospitalization period as an opportunity to address high A1c levels is thus crucial. Disclosure S.P. Masiano: None. L.G. Tereshchenko: None. V. Chepp: None. A. Milinovich: Research Support; Novo Nordisk, Bayer Inc., Merck AstraZeneca. Consultant; AstraZeneca. Board Member; Bayer Inc. Research Support; Bayer Inc. Speaker's Bureau; Corcept Therapeutics. Consultant; Corcept Therapeutics, Diasome, Eli Lilly and Company, Merck Merck Merck Novo Nordisk. Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Research Support; Twin Health. Consultant; Sanofi. A.D. Misra-Hebert: Research Support; Bayer Inc., Merck & Co., Inc., Novo Nordisk. Funding This work was internally supported with funding from the Healthcare Delivery and Implementation Science Center at Cleveland Clinic.